113 related articles for article (PubMed ID: 28752290)
1. Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases.
Schuller Y; Hollak CEM; Gispen-de Wied CC; Stoyanova-Beninska V; Biegstraaten M
Drugs; 2017 Sep; 77(13):1461-1472. PubMed ID: 28752290
[TBL] [Abstract][Full Text] [Related]
2. Oncologic orphan drugs approved in the EU - do clinical trial data correspond with real-world effectiveness?
Schuller Y; Biegstraaten M; Hollak CEM; Klümpen HJ; Gispen-de Wied CC; Stoyanova-Beninska V
Orphanet J Rare Dis; 2018 Nov; 13(1):214. PubMed ID: 30486835
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence for orphan medicinal products-a cause for concern?
Picavet E; Cassiman D; Hollak CE; Maertens JA; Simoens S
Orphanet J Rare Dis; 2013 Oct; 8():164. PubMed ID: 24131572
[TBL] [Abstract][Full Text] [Related]
4. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
[No Abstract] [Full Text] [Related]
5. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Heard JM; Vrinten C; Schlander M; Bellettato CM; van Lingen C; Scarpa M;
Orphanet J Rare Dis; 2020 Jan; 15(1):3. PubMed ID: 31907071
[TBL] [Abstract][Full Text] [Related]
6. [The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs.].
Crisafulli S; Trifirò G
Recenti Prog Med; 2022; 113(7):425-429. PubMed ID: 35852077
[TBL] [Abstract][Full Text] [Related]
7. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
8. Determinants for successful marketing authorisation of orphan medicinal products in the EU.
Putzeist M; Heemstra HE; Garcia JL; Mantel-Teeuwisse AK; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2012 Apr; 17(7-8):352-8. PubMed ID: 22094244
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
10. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs.
Maeda K; Kaneko M; Narukawa M; Arato T
Orphanet J Rare Dis; 2017 Aug; 12(1):143. PubMed ID: 28835285
[TBL] [Abstract][Full Text] [Related]
11. Dose-Finding Studies Among Orphan Drugs Approved in the EU: A Retrospective Analysis.
Schuller Y; Gispen-de Wied C; Hollak CEM; Leufkens HGM; Stoyanova-Beninska V
J Clin Pharmacol; 2019 Feb; 59(2):229-244. PubMed ID: 30192386
[TBL] [Abstract][Full Text] [Related]
12. Drug Repurposing for Rare Diseases: A Role for Academia.
van den Berg S; de Visser S; Leufkens HGM; Hollak CEM
Front Pharmacol; 2021; 12():746987. PubMed ID: 34744726
[No Abstract] [Full Text] [Related]
13. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
14. Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010-2019.
Foltanova T; Majernik A; Malikova E; Kosirova S
Front Pharmacol; 2022; 13():768325. PubMed ID: 35153774
[No Abstract] [Full Text] [Related]
15. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
16. Medicine characteristics affecting the time to guidance publication by National Institute for Health and Care Excellence in the single technology appraisal process.
Takada S; Narukawa M
Int J Technol Assess Health Care; 2021 Dec; 38(1):e11. PubMed ID: 34933699
[TBL] [Abstract][Full Text] [Related]
17. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
18. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
Pijeira Perez Y; Wood E; Hughes DA
Orphanet J Rare Dis; 2023 Nov; 18(1):342. PubMed ID: 37915031
[TBL] [Abstract][Full Text] [Related]
19. EU marketing authorization review of orphan and non-orphan drugs does not differ.
Putzeist M; Mantel-Teeuwisse AK; Llinares J; Gispen-De Wied CC; Hoes AW; Leufkens HG
Drug Discov Today; 2013 Oct; 18(19-20):1001-6. PubMed ID: 23835230
[TBL] [Abstract][Full Text] [Related]
20. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
